LOH12CR2: A Potential Drug Target and Biomarker (G503693)

Target Name: LOH12CR2

NCBI ID: G503693

Other Name(s): LOH2CR12 | Loss of heterozygosity on chromosome 12, region 2 | loss of heterozygosity on chromosome 12, region 2

LOH12CR2: A Potential Drug Target and Biomarker

Introduction

LOH12CR2 is a gene that encodes a protein known as long non-coding RNA (lncRNA). LncRNA is a class of RNA molecules that has been identified as a potential drug target and biomarker in various diseases, including cancer. LOH12CR2 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. The identification of LOH12CR2 as a potential drug target and biomarker has led to a growing interest in the development of new therapeutic approaches for various diseases.

Clinical Significance

LOH12CR2 has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that LOH12CR2 is overexpressed in various types of cancer, including breast, lung, and colorectal cancer. Additionally, LOH12CR2 has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes in cancer progression.

One of the key challenges in the development of new therapeutic approaches for cancer is the difficulty of targeting specific genes within the complex cellular network that drives cancer growth. LOH12CR2 provides a potential solution to this problem by serving as a drug target that can be targeted with small molecules or antibodies.

In addition to its potential as a drug target, LOH12CR2 has also been shown to be a potential biomarker for cancer. The expression of LOH12CR2 has been shown to be associated with the development and progression of various types of cancer. For example, studies have shown that LOH12CR2 is expressed in various types of cancer and that it is associated with poor prognosis in cancer patients.

Despite the potential for LOH12CR2 as a drug target and biomarker, much research is still needed to fully understand its role in cancer. Understanding the molecular mechanisms that drive LOH12CR2's involvement in cancer biology will be critical for the development of new therapeutic approaches for cancer.

Molecular Mechanisms

The molecular mechanisms that are underlying LOH12CR2's involvement in cancer biology are still not fully understood. However, studies have shown that LOH12CR2 is involved in several cellular processes that are critical in cancer progression.

One of the key mechanisms through which LOH12CR2 is involved in cancer progression is its role in cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. LOH12CR2 has been shown to be involved in the regulation of cell adhesion, which is critical for the development of tissues and organs.

In addition to its role in cell adhesion, LOH12CR2 is also involved in the regulation of cell migration. Migration is the process by which cells move from one location to another in the body. LOH12CR2 has been shown to be involved in the regulation of cell migration. , which is critical for the development of tumors.

Furthermore, LOH12CR2 is also involved in the regulation of apoptosis, which is the process by which cells die. LOH12CR2 has been shown to be involved in the regulation of apoptosis, which is critical for the control of cell growth and the regulation of cancer progression.

Drug Targeting

The potential of LOH12CR2 as a drug target is based on its involvement in several cellular processes that are critical in cancer progression. LOH12CR2 has been shown to be an attractive target for small molecules and antibodies due to its stability, broad expression, and the potential for modulation by small molecules.

One of the key challenges in the development of new therapeutic approaches for cancer is the difficulty of targeting specific genes within the complex cellular network that drives cancer growth. To address this challenge, researchers have developed several strategies to

Protein Name: Loss Of Heterozygosity On Chromosome 12, Region 2

More Common Targets